• Joelle Kefer
  • Tom de Potter
  • Francis Stammen
  • Edouard Benit
  • Werner Budts
  • Luc Missault
  • Benny Drieghe
  • Ian Buysschaert
  • Kristoff Cornelis
  • Jean-Manuel Herzet
  • Antoine Guedes
  • Nadia Debbas
  • Maximo Rivero
  • Mathieu Lempereur
  • Christophe Laruelle
  • Philippe Debruyne
  • Thierry Ledent

AIMS: This study aimed to assess the safety and efficacy at midterm follow-up of left atrial appendage occlusion (LAAO) using different devices, in real life in Belgium.

METHODS AND RESULTS: Between June 2009 and November 2016, 457 consecutive patients (63% male, 75±12 yrs, CHA2DS2-VASc 4±0.6, HAS-BLED 3.5±0.7) undergoing LAAO were included. Technical success was 97.1%. There were 19 periprocedural major adverse events (4.1%) including three deaths (0.6%), nine tamponades (1.9%), four major bleedings (0.8%) and two device embolisations (0.4%). Among patients successfully implanted having a complete follow-up (672 patient-years, median follow-up 370 days), the actual annual stroke rate was 1.2%, lower than the expected stroke risk of 4% (70% reduction). The observed bleeding rate was 2%, while the calculated risk was 3.7% (46% reduction). Kaplan-Meier analysis showed a similar overall survival (93±2% and 87±3% versus 91±3% and 87±4%; p=0.35) and event-free survival (92±2% and 84±3% versus 88±3% and 80±5%; p=0.17) at one and two years, for the ACP/Amulet versus the WATCHMAN groups of patients, respectively.

CONCLUSIONS: The data from the Belgian left atrial appendage occlusion registry suggest that the procedure is effective and relatively safe in a real-world setting, using either the WATCHMAN or the ACP/Amulet device.

Original languageEnglish
Pages (from-to)1603-1611
Number of pages9
Issue number13
Publication statusPublished - 20 Jan 2018

    Research areas

  • Atrial fibrillation, Bleeding, Specific device closure/technique, Stroke

ID: 36884650